MannKind Corporation - Common Stock (NQ:MNKD)

4.060 +0.160 (+4.10%)

Delayed Quote Updated: 1:40 PM EDT, Oct 1, 2026 Add to My Watchlist

Price and Volume

Volume	5,368,728
Open	3.840
Bid (Size)	4.050 (4,900)
Ask (Size)	4.060 (5,500)
Prev. Close	3.900
Today's Range	3.830 - 4.225
52wk Range	2.230 - 6.510
Shares Outstanding	264,305,532
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains Momentum ↗

September 17, 2026

MannKind (NASDAQ:MNKD) CFO Chris Prentiss outlined the company’s commercial and development priorities at the H.C. Wainwright Global Investment Conference, emphasizing execution following three major...

Via MarketBeat

MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management

September 09, 2026

From MannKind

Via GlobeNewswire

Performance

YTD	-27.5%	-27.5%
1 Month	+1.2%	+1.2%
3 Month	+0.2%	+0.2%
6 Month	+59.8%	+59.8%
1 Year	-24.4%	-24.4%

More News

MannKind to Present at Upcoming Investor Conferences

September 02, 2026

From MannKind

Via GlobeNewswire

MannKind Q2 Earnings Call Highlights ↗

August 05, 2026

Via MarketBeat

MannKind (NASDAQ:MNKD) Falls as Q2 EPS Miss Overshadows In-Line Revenue ↗

August 05, 2026

Via Chartmill

MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update

August 05, 2026

From MannKind

Via GlobeNewswire

MannKind’s Inhaled IPF Drug Clears Phase 1b Safety Hurdle, Phase 2 Underway ↗

July 29, 2026

Via MarketBeat

MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF

July 29, 2026

From MannKind

Via GlobeNewswire

MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026

July 28, 2026

From MannKind

Via GlobeNewswire

MannKind Wins FDA Approval for Furoscix ReadyFlow, Secures $50M PIPE ↗

July 24, 2026

Via MarketBeat

MannKind Announces $50 Million Private Placement

July 24, 2026

From MannKind

Via GlobeNewswire

MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease

July 24, 2026

From MannKind

Via GlobeNewswire

What This MannKind Filing Reveals About Three Years of Underperformance ↗

July 20, 2026

Via The Motley Fool

What This MannKind Director Sale Signals With $32.7 Million in Quarterly Royalties Revenue Potentially at Risk ↗

July 20, 2026

Via The Motley Fool

What This MannKind Sale Signals With Tyvaso Royalties at $32.7 Million ↗

July 20, 2026

Via The Motley Fool

Why This MannKind Insider Stock Sale Matters Less Than a 9% Royalty at Risk ↗

July 20, 2026

Via The Motley Fool

Is MannKind a Stock to Sell After Its CEO Let Go of 363,200 Shares? ↗

July 19, 2026

Via The Motley Fool

MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D

June 23, 2026

From MannKind

Via GlobeNewswire

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems

June 05, 2026

From MannKind

Via GlobeNewswire

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF

June 03, 2026

From MannKind

Via GlobeNewswire

MannKind Wins FDA Approval for Afrezza in Children, Opening Pediatric Diabetes Market ↗

May 30, 2026

Via MarketBeat

MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval

May 29, 2026

From MannKind

Via GlobeNewswire

MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes

May 29, 2026

From MannKind

Via GlobeNewswire

MannKind to Present at Jefferies Global Healthcare Conference

May 27, 2026

From MannKind

Via GlobeNewswire

MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems

May 27, 2026

From MannKind

Via GlobeNewswire

Frequently Asked Questions

Is MannKind Corporation - Common Stock publicly traded?

Yes, MannKind Corporation - Common Stock is publicly traded.

What exchange does MannKind Corporation - Common Stock trade on?

MannKind Corporation - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for MannKind Corporation - Common Stock?

The ticker symbol for MannKind Corporation - Common Stock is MNKD on the Nasdaq Stock Market

What is the current price of MannKind Corporation - Common Stock?

The current price of MannKind Corporation - Common Stock is 4.060

When was MannKind Corporation - Common Stock last traded?

The last trade of MannKind Corporation - Common Stock was at 10/01/26 01:40 PM ET

What is the market capitalization of MannKind Corporation - Common Stock?

The market capitalization of MannKind Corporation - Common Stock is 1.07B

How many shares of MannKind Corporation - Common Stock are outstanding?

MannKind Corporation - Common Stock has 1B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.